Plasma Epstein-Barr virus DNA as a biomarker for nasopharyngeal carcinoma

Chinese Journal of Cancer

Volumn 33, Issue 12, 2014, Pages 598-603

  Allen Chan, K C ^a,b  

^a CHINESE UNIVERSITY OF HONG KONG   (Hong Kong)

^b CHINESE UNIVERSITY OF HONG KONG   (Hong Kong)

Author keywords

Cancer screening; Nasopharyngeal carcinoma; Plasma Epstein Barr virus EBV DNA; Tumor markers

Indexed keywords

BIOLOGICAL MARKER; VIRUS DNA;

CHINA; EPSTEIN BARR VIRUS; EPSTEIN BARR VIRUS INFECTION; HUMAN; NASOPHARYNX TUMOR; REAL TIME POLYMERASE CHAIN REACTION; VIROLOGY;

BIOMARKERS; CHINA; DNA, VIRAL; EPSTEIN-BARR VIRUS INFECTIONS; HERPESVIRUS 4, HUMAN; HUMANS; NASOPHARYNGEAL NEOPLASMS; REAL-TIME POLYMERASE CHAIN REACTION;

EID: 84914176287     PISSN: 1000467X     EISSN: 1944446X     Source Type: Journal    
DOI: 10.5732/cjc.014.10192     Document Type: Review

References (43)

1. [1] Wei WI, Sham JS. Nasopharyngeal carcinoma. Lancet, 2005, 365:2041-2054.
2. [2] Yeung WM, Zong YS, Chiu CT, et al. Epstein-Barr virus carriage by nasopharyngeal carcinoma in situ. Int J Cancer, 1993,53:746-750.
3. [3] Mutirangura A, Pornthanakasem W, Theamboonlers A, et al. Epstein-Barr viral DNA in serum of patients with nasopharyngeal carcinoma. Clin Cancer Res, 1998,4:665-669.
4. [4] Lit LCW, Chan KCA, Leung SF, et al. Distribution of cell-free and cell-associated Epstein-Barr virus (EBV) DNA in the blood of patients with nasopharyngeal carcinoma and EBV-associated lymphoma. Clin Chem, 2004,50:1842-1845.
5. [5] Lo YMD, Chan LYS, Lo KW, et al. Quantitative analysis of cell-free Epstein-Barr virus DNA in plasma of patients with nasopharyngeal carcinoma. Cancer Res, 1999,59:1188-1191.
6. [6] Leung SF, Tam JS, Chan ATC, et al. Improved accuracy of detection of nasopharyngeal carcinoma by combined application of circulating Epstein-Barr virus DNA and anti-Epstein-Barr viral capsid antigen IgA antibody. Clin Chem, 2004,50:339-345.
7. [7] Leung SF, Zee B, Ma BB, et al. Plasma Epstein-Barr viral deoxyribonucleic acid quantitation complements tumor-node-metastasis staging prognostication in nasopharyngeal carcinoma. J Clin Oncol, 2006,24:5414-5418.
8. [8] Shao JY, Li YH, Gao HY, et al. Comparison of plasma Epstein- Barr virus (EBV) DNA levels and serum EBV immunoglobulin A/ virus capsid antigen antibody titers in patients with nasopharyngeal carcinoma. Cancer, 2004,100:1162-1170.
9. [9] Kondo S, Horikawa T, Takeshita H, et al. Diagnostic value of serum EBV-DNA quantification and antibody to viral capsid antigen in nasopharyngeal carcinoma patients. Cancer Sci, 2004,95:508-513.
10. [10] Chan AKC, Chiu RWK, Lo YMD. Cell-free nucleic acids in plasma, serum and urine: a new tool in molecular diagnosis. Ann Clin Biochem, 2003,40:122-130.
11. [11] Chan KCA, Lo YMD. Circulating EBV DNA as a tumor marker for nasopharyngeal carcinoma. Semin Cancer Biol, 2002,12:489-496.
12. [12] Chan KCA, Lo YMD. Circulating tumour-derived nucleic acids in cancer patients: potential applications as tumour markers. Br J Cancer, 2007,96:681-685.
13. [13] Ma BB, King A, Lo YM, et al. Relationship between pretreatment level of plasma Epstein-Barr virus DNA, tumor burden, and metabolic activity in advanced nasopharyngeal carcinoma. Int J Radiat Oncol Biol Phys, 2006,66:714-720.
14. [14] Chan KCA, Chan AT, Leung SF, et al. Investigation into the origin and tumoral mass correlation of plasma Epstein-Barr virus DNA in nasopharyngeal carcinoma. Clin Chem, 2005,51:2192-2195.
15. [15] Lo YMD. Prognostic implication of pretreatment plasma/serum concentration of Epstein-Barr virus DNA in nasopharyngeal carcinoma. Biomed Pharmacother, 2001,55:362-365.
16. [16] Wang WY, Twu CW, Chen HH, et al. Long-term survival analysis of nasopharyngeal carcinoma by plasma Epstein-Barr virus DNA levels. Cancer, 2013,119:963-970.
17. [17] Lo YMD, Chan ATC, Chan LYS, et al. Molecular prognostication of nasopharyngeal carcinoma by quantitative analysis of circulating Epstein-Barr virus DNA. Cancer Res, 2000,60:6878-6881.
18. [18] To EW, Chan KCA, Leung SF, et al. Rapid clearance of plasma Epstein-Barr virus DNA after surgical treatment of nasopharyngeal carcinoma. Clin Cancer Res, 2003,9:3254-3259.
19. [19] Chan KCA, Zhang J, Chan ATC, et al. Molecular characterization of circulating EBV DNA in the plasma of nasopharyngeal carcinoma and lymphoma patients. Cancer Res, 2003,63:2028-2032.
20. [20] Jahr S, Hentze H, Englisch S, et al. DNA fragments in the blood plasma of cancer patients: quantitations and evidence for their origin from apoptotic and necrotic cells. Cancer Res, 2001,61:1659-1665.
21. [21] Diehl F, Li M, Dressman D, et al. Detection and quantification of mutations in the plasma of patients with colorectal tumors. Proc Natl Acad Sci U S A, 2005,102:16368-16373.
22. [22] Lo YMD, Leung SF, Chan LYS, et al. Kinetics of plasma Epstein- Barr virus DNA during radiation therapy for nasopharyngeal carcinoma. Cancer Res, 2000,60:2351-2355.
23. [23] Hsu CL, Chang KP, Lin CY, et al. Plasma Epstein-Barr virus DNA concentration and clearance rate as novel prognostic factors for metastatic nasopharyngeal carcinoma. Head Neck, 2012,34:1064- 1070.
24. [24] Wang WY, Twu CW, Chen HH, et al. Plasma EBV DNA clearance rate as a novel prognostic marker for metastatic/recurrent nasopharyngeal carcinoma. Clin Cancer Res, 2010,16:1016-1024.
25. [25] Lo YMD, Chan LYS, Chan ATC, et al. Quantitative and temporal correlation between circulating cell-free Epstein-Barr virus DNA and tumor recurrence in nasopharyngeal carcinoma. Cancer Res, 1999,59:5452-5455.
26. [26] Wang WY, Twu CW, Lin WY, et al. Plasma Epstein-Barr virus DNA screening followed by (18)F-fluoro-2-deoxy-D-glucose positron emission tomography in detecting posttreatment failures of nasopharyngeal carcinoma. Cancer, 2011,117:4452-4459.
27. [27] Chan ATC, Lo YMD, Zee B, et al. Plasma Epstein-Barr virus DNA and residual disease after radiotherapy for undifferentiated nasopharyngeal carcinoma. J Natl Cancer Inst, 2002,94:1614-1619.
28. [28] An X, Wang FH, Ding PR, et al. Plasma Epstein-Barr virus DNA level strongly predicts survival in metastatic/recurrent nasopharyngeal carcinoma treated with palliative chemotherapy. Cancer, 2011,117:3750-3757.
29. [29] Ferrari D, Codeca C, Bertuzzi C, et al. Role of plasma EBV DNA levels in predicting recurrence of nasopharyngeal carcinoma in a western population. BMC Cancer, 2012,12:208.
30. [30] Lin JC, Wang WY, Chen KY, et al. Quantification of plasma Epstein-Barr virus DNA in patients with advanced nasopharyngeal carcinoma. N Engl J Med, 2004,350:2461-2470.
31. [31] Hou X, Zhao C, Guo Y, et al. Different clinical significance of pre- and post-treatment plasma Epstein-Barr virus DNA load in nasopharyngeal carcinoma treated with radiotherapy. Clin Oncol (R Coll Radiol), 2011,23:128-133.
32. [32] Le QT, Zhang Q, Cao H, et al. An international collaboration to harmonize the quantitative plasma Epstein-Barr virus DNA assay for future biomarker-guided trials in nasopharyngeal carcinoma. Clin Cancer Res, 2013,19:2208-2215.
33. [33] Lee AW, Sze WM, Au JS, et al. Treatment results for nasopharyngeal carcinoma in the modern era: the Hong Kong experience. Int J Radiat Oncol Biol Phys, 2005,61:1107-1116.
34. [34] Chan KCA, Hung ECW, Woo JKS, et al. Early detection of nasopharyngeal carcinoma by plasma Epstein-Barr virus DNA analysis in a surveillance program. Cancer, 2013,119:1838-1844.
35. [35] Chien YC, Chen JY, Liu MY, et al. Serologic markers of Epstein-Barr virus infection and nasopharyngeal carcinoma in Taiwanese men. N Engl J Med, 2001,345:1877-1882.
36. [36] Chan KCA, Leung SF, Yeung SW, et al. Quantitative analysis of the transrenal excretion of circulating EBV DNA in nasopharyngeal carcinoma patients. Clin Cancer Res, 2008,14:4809-4813.
37. [37] Ma AT, Ma BB, Teo PM, et al. A novel application of plasma and cerebrospinal fluid level of Epstein-Barr virus DNA in the diagnosis of leptomeningeal metastasis from nasopharyngeal carcinoma. A case report. Oncology, 2008,74:119-122.
38. [38] Yung TKF, Chan KCA, Mok TSK, et al. Single-molecule detection of epidermal growth factor receptor mutations in plasma by microfluidics digital pcr in non-small cell lung cancer patients. Clin Cancer Res, 2009,15:2076-2084.
39. [39] Forshew T, Murtaza M, Parkinson C, et al. Noninvasive identification and monitoring of cancer mutations by targeted deep sequencing of plasma DNA. Sci Transl Med, 2012,4:136-168.
40. [40] Leary RJ, Kinde I, Diehl F, et al. Development of personalized tumor biomarkers using massively parallel sequencing. Sci Transl Med, 2010,2:20ra14.
41. [41] Chan KCA. Scanning for cancer genomic changes in plasma: toward an era of personalized blood-based tumor markers. Clin Chem, 2013,59:1553-1555.
42. [42] Chan KCA, Jiang P, Zheng YW, et al. Cancer genome scanning in plasma: detection of tumor-associated copy number aberrations, single-nucleotide variants, and tumoral heterogeneity by massively parallel sequencing. Clin Chem, 2013,59:211-224.
43. [43] Chan KCA, Jiang P, Chan CWM, et al. Noninvasive detection of cancer-associated genomewide hypomethylation and copy number aberrations by plasma DNA bisulfite sequencing. Proc Natl Acad Sci USA, 2013,110:18761-18768.